The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies. Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to […]
Share:
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies.
Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to 2028.
Look out for the Evaluate Vantage Medtech World Preview, coming soon.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
